Press Releases

Date Title and Summary Additional Formats
Toggle Summary Quotient Limited Announces Receipt of Consents to Modifications to the Company’s Senior Secured Notes
JERSEY, Channel Islands , Dec. 04, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced the receipt of consents from the holders of its Senior Secured Notes (the Notes) to certain amendments (the Proposed Amendments) to the
View HTML
Toggle Summary Quotient Limited Announces Initial MosaiQ™ SDS Verification and Validation Data
JERSEY, Channel Islands , Dec. 03, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today reported positive Verification and Validation (V&V) concordance data for its initial MosaiQ™ Serological Disease Screening (SDS) Microarray.
View HTML
Toggle Summary Quotient Limited Reports Positive MosaiQ Audit Results and Instrument CE Mark with Second Quarter Fiscal 2019 Financial Results
Positive MosaiQ manufacturing facility audit results MosaiQ instrument CE mark self certification complete Year to date reagent product revenues growing at 16% JERSEY, Channel Islands , Nov. 05, 2018 (GLOBE NEWSWIRE) --   Quotient Limited (NASDAQ: QTNT) (Quotient or the Company), a commercial-stage
View HTML
Toggle Summary Quotient Limited to Participate in the Jefferies 2018 London Healthcare Conference
JERSEY, Channel Islands , Oct. 31, 2018 (GLOBE NEWSWIRE) -- Quotient (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chief Financial Officer, Chris Lindop, will present at the Jefferies 2018 London Healthcare Conference on Wednesday, November 14 th , 2018
View HTML
Toggle Summary Quotient Limited to Report Fiscal Second Quarter 2019 Financial Results and Host Conference Call
JERSEY, Channel Islands , Oct. 22, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal second quarter ended September 30, 2018 , will be released before market open on Monday, November 5, 2018 .
View HTML
Toggle Summary Quotient Limited to Participate in the 2018 Cantor Fitzgerald Global Healthcare Conference
JERSEY, Channel Islands , Sept. 26, 2018 (GLOBE NEWSWIRE) -- Quotient (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive Officer, Franz Walt , will present at the 2018 Cantor Fitzgerald Global Healthcare Conference on Wednesday,
View HTML
Toggle Summary Quotient Limited reports the submission of the initial IH CE mark filing and the successful completion of the key regulatory audits of its new BioCampus facility
Initial IH CE mark submission has been completed and filed on schedule Successful facility audits pave the way for an on time BioCampus ramp up JERSEY, Channel Islands , Sept. 25, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today reported: (i)
View HTML
Toggle Summary Quotient Limited Reports Senior Note Issuance and Warrant Cash Inflows and updates on MosaiQ Development and First Quarter Fiscal 2019 Financial Results
$48.8 million of proceeds from warrant exercises received through July 31 $36 million of additional senior notes issued and funded in June Initial SDS microarray verification and validation started Record reagent revenues recorded during the quarter JERSEY, Channel Islands , Aug.
View HTML
Toggle Summary Quotient Limited to Report Fiscal First Quarter 2019 Financial Results and Host Conference Call
JERSEY, Channel Islands , July 24, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal first quarter ended June 30, 2018 , will be released after market close on Monday, August 6, 2018 .
View HTML
Toggle Summary Quotient Limited Announces Details of Investor Day
JERSEY, Channel Islands , July 16, 2018 (GLOBE NEWSWIRE) -- Quotient Limited  (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced details of its investor day held at the NASDAQ headquarters in New York earlier today. Following the recent announcement of positive field trial data
View HTML